Imaging Technology

MAY 23, 2023

milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C.

Radiation Oncology 67

Radiation Oncology Radiation Clinic Medicare 67

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We

Medical 88

Medical Radiopharmaceuticals Pharmaceutical Radiation 88

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies. tesla and 3T scanners.

Hospital 100

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 100

Imaging Technology

JANUARY 12, 2024

Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.

Radiopharmaceuticals 98

Radiopharmaceuticals Radiation Medicare Clinic 98

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 93

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 93

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 79

Medical Radiopharmaceuticals Pharmaceutical Radiation 79

Imaging Technology

AUGUST 29, 2023

Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue. It supports a sustainable future for radiopharmaceuticals unencumbered by manufacturing, logistical and environmental issues inherent to many radiopharmaceuticals.

Pharmaceutical 73

Pharmaceutical Radiopharmaceuticals Clinic Medical 73

Future Teleradiology

NOVEMBER 27, 2023

Discuss how this approach delivers radiation with exceptional precision to cancer cells. Advances in Cardiac Imaging: Precision in Heart Disease Diagnosis: Highlight recent breakthroughs in cardiac imaging within nuclear medicine. Discuss how these compounds are expanding therapeutic options for various diseases, including cancer.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.

Clinic 79

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 79

AuntMinnie

MARCH 25, 2024

Coronary artery disease (CAD) is the leading cause of mortality in the U.S. In a cohort of 1,282 patients who underwent invasive coronary angiography for suspected disease, noninvasive PET MPI performed within six months identified large perfusion defects (>10% of the left ventricular myocardium) in 82% of the patients.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

Imaging Technology

AUGUST 23, 2023

SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion.

Radiopharmaceuticals 83

Radiopharmaceuticals Disease Radiation Clinic 83

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 61

Medical Radiopharmaceuticals Pharmaceutical Radiation 61

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.

Diagnostic 89

Diagnostic Radiopharmaceuticals Imaging Radiation 89

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 87

Nuclear Medicine Radiation Oncology Nursing Radiation 87

Future Teleradiology

NOVEMBER 21, 2023

Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals. Personalized Dosimetry: Optimizing Therapeutic Radiation Doses: Discuss the importance of personalized dosimetry.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology 52

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic 90

Diagnostic Radiation Oncology Radiation Clinic 90

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic 72

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 72

Imaging Technology

JULY 28, 2023

POSLUMA represents a new class of high-affinity PSMA-targeted PET radiopharmaceuticals based on novel radiohybrid technology and is labeled with the radioisotope 18F to provide readily available patient access and leverage the high image quality of 18F-labeled PSMA PET imaging to facilitate effective detection of disease.

Clinic 81

Clinic Diagnostic Radiopharmaceuticals Radiation 81